Health-Care Stocks Save the S&P 500 From Stumbling as the Dow Slumbers

All three of the major American stock indices have recovered quickly from fairly large opening-bell dips to trade just above breakeven at lunchtime on Monday. Most of the Dow Jones Industrial Average's (DJINDICES: ^DJI  ) 30 components are trading slightly lower -- only eight had produced gains of greater than 0.25% shortly before noon EDT -- but roughly 225 of the broader S&P 500's (SNPINDEX: ^GSPC  ) components are in positive territory.

Last week's divergent economic news of disappointing first-quarter gross domestic product growth but a solid uptick in employee hires left many investors unsure of what to do, and the start of this week hasn't provided much certainty yet. Weakness in China's closely watched manufacturing index and the fear of further military escalation between Russia and Ukraine have thus far been offset by a strong Institute for Supply Management report on nonmanufacturing productivity.

That gauge of service-sector production hit a new orders number of 58.2 (anything below 50 signals recession) in March, which is its strongest level this year and also slightly higher than September's 58.1 mark. The overall PMI was 55.2. It appears that the Dow's industrially focused stocks are reaping most of the rewards of the service-sector report, as Boeing, DuPont, and energy giants ExxonMobil and Chevron are four of the Dow's strongest today.

Only Disney (NYSE: DIS  ) is leading a charge for the Dow's numerous service-focused stocks, as its 0.9% rise puts it neck and neck with ExxonMobil's for the second-best gain of all 30 components -- only Boeing has gained over 1% so far today. Topeka Capital today upgraded the House of Mouse's shares to buy status, with a new $91 price target. The new price target gives Disney shares about 12% of further upside, which is a pretty modest expectation for a stock that has already gained over 25% in the past year. Boeing, for its part, continues to ride the positive sentiment generated by a solid sales report released on Friday. Fool aerospace and defense specialist Rich Smith has all the juicy details: in short, the airplane maker has collected 13% more orders this year than it did at the same point in 2013.

Source: Darren Hester via DeviantArt.

The Dow might be languishing, but the S&P has a very narrow edge on its smaller peer today thanks to a broad-based but not particularly powerful gain in many larger health-care stocks. The S&P's biggest gainer, shortly before noon, was Biogen Idec, but other biotech heavyweights including Gilead Sciences (NASDAQ: GILD  ) , Alexion Pharmaceuticals, and Vertex Pharmaceuticals were among the index's leaders today. Both CVS Caremark (NYSE: CVS  ) and Walgreen were also among the S&P's 20 best-performing stocks so far.

Of these gainers, all but Alexion have developed a hepatitis treatment, and Gilead's market-destroying sales of apparent blockbuster (and wallet-buster) hepatitis C treatment Sovaldi has given many rivals reasons to be optimistic as well, provided they can also achieve a measure of success with their treatments. CVS reported first-quarter earnings on Friday evening, and it is clearly growing strongly for such a large and well-established retail company. For Biogen, Gilead, and pharmacy chains CVS and Walgreen, it seems likely that Obamacare's evident success in signing up more people for health insurance than it had promised has created positive momentum beyond what investors might have hoped for otherwise. Last Wednesday's GDP report supports this idea, as unprecedented growth in the health-care sector was really the only thing standing between the American economy and a mild recession in the first quarter.

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2943539, ~/Articles/ArticleHandler.aspx, 8/28/2014 1:14:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement